¸¤¼ïÊÌ°äÅÁÀ¼À´µ(07ǯÅÙÅÐϿƬ¿ô½ç) | 1°Ì¥À¥Ã¥¯¥¹¥Õ¥ó¥È | 2°Ì¥Á¥ï¥ï | 3°Ì¥×¡¼¥É¥ë | 4°Ì¥è¡¼¥¯¥·¥ã¡¼¥Æ¥ê¥¢ | 5°Ì¥Ý¥á¥é¥Ë¥¢¥ó |
---|
ʬÎà | ¼À´µÌ¾(ÏÂ̾) | ¼À´µÌ¾(±Ñ̾) | ¼ç ¤Ê ¾É ¾õ | °äÅÁ·ÁÂÖ | ¸¡ººµ¡´Ø | È÷¹Í |
---|
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤Î¾É¾õ¤Ç»ëÎÏÄã²¼¤Ëµ¤ÉÕ¤¯¡£·ë²ÌŪ¤Ë¤Ï¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¥ê¥Æ¥¤¥ë | ||||||
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
»°É© | ||||||
Progressive Retinal Atrophy(PRA) | GTG | |||||
·ì±Õ | Çò·ìµåÇ´ÃåÉÔÁ´¾É | Leukocyte adhesion deficiency | Çò·ìµå¤ËºÙ¶Ý¤ò¤ä¤Ã¤Ä¤±¤ëÎϤ¬Ìµ¤¤¤¿¤á¤Ë¡¢Ä̾ï¤Ê¤ó¤Ç¤â¤Ê¤¤¶Ý¤ËÉ餱¤Æ¤·¤Þ¤¦Éµ¤¡£¤Ø¤½¤Î½ï¤¬¼è¤ì¤ë¤Þ¤Ç»þ´Ö¤¬¤«¤«¤ë¡£¼£¤ê¤Ë¤¯¤¤²¼Î¡¡¢È¯Ç®¡£»õ¤¬À¸¤¨¤ëÁ°¤«¤é»õÆù±ê¤Ê¤É¡£À®Ä¹¤¬ÃÙ¤¤¡£Â¿¤¯¤Ï´¶À÷¾É¤Ë¤è¤êÁá´ü¤Ë»àË´¡£ÀèÅ·À¹¥Ãæµåµ¡Ç½°Û¾ï¾É¤Î¤Ò¤È¤Ä¡£ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
¥¤¥ÌÇò·ìµåÇ´ÃåÉÔÁ´¾É | Canine Leukocyte Adhesion Deficiency(CLAD) | GTG |
·ì±Õ | Çò·ìµåÇ´ÃåÉÔÁ´¾É | Leukocyte adhesion deficiency | Çò·ìµå¤ËºÙ¶Ý¤ò¤ä¤Ã¤Ä¤±¤ëÎϤ¬Ìµ¤¤¤¿¤á¤Ë¡¢Ä̾ï¤Ê¤ó¤Ç¤â¤Ê¤¤¶Ý¤ËÉ餱¤Æ¤·¤Þ¤¦Éµ¤¡£¤Ø¤½¤Î½ï¤¬¼è¤ì¤ë¤Þ¤Ç»þ´Ö¤¬¤«¤«¤ë¡£¼£¤ê¤Ë¤¯¤¤²¼Î¡¡¢È¯Ç®¡£»õ¤¬À¸¤¨¤ëÁ°¤«¤é»õÆù±ê¤Ê¤É¡£À®Ä¹¤¬ÃÙ¤¤¡£Â¿¤¯¤Ï´¶À÷¾É¤Ë¤è¤êÁá´ü¤Ë»àË´¡£ÀèÅ·À¹¥Ãæµåµ¡Ç½°Û¾ï¾É¤Î¤Ò¤È¤Ä¡£ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ξÌܤ¬¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£¸¤¼ïº¹¤ä¸ÄÂκ¹¤Ï¤¢¤ë¤¬°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | GTG | ||||
Âå¼Õ | ¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼·ç»¾É | Phosphofructokinase Deficiency | ¡Ö²òÅü·Ï¹ÚÁǤΣ±¤Ä¤Ç¤¢¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¤Î·ç»¤¬¸¶°ø¤Ç¡¢¿·À¸»ù¤Ç¤ÏÃ×»àÀ¤È¤Ê¤ë¤³¤È¤Î¤¢¤ëɵ¤¤Ç¤¹¡£¡×(¥ê¥Æ¥¤¥ë) ¡ÖÀÖ·ìµå¤ä¶ÚÆù¤Ê¤É¤Ç¥¨¥Í¥ë¥®¡¼¸»¤Ç¤¢¤ë¥°¥ë¥³¡¼¥¹¤ä¥°¥ê¥³¡¼¥²¥ó¤ÎÂå¼Õ¤Ë´Ø¤ï¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¡ÊPFK¡Ë¤Ë°Û¾ï¤¬µ¯¤³¤ëɵ¤¤Ç¤¹¡£¥¨¥Í¥ë¥®¡¼¤¬ÉÔ¤¹¤ë¤³¤È¤Ë¤Ê¤ë¤Î¤Çµõ¼å¡¢¶ÚÆù¤ÎáÛÚ»¡¢²«áÕ¤¬¸«¤é¤ì¤Þ¤¹¡£¡×(¥ê¥ó¥¯¥¹) |
AR | ¥ê¥Æ¥¤¥ë | »à»º¡¢¿·À¸»ù»àË´ |
»°É© | ||||||
¥Û¥¹¥Û¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼·ç»¾É | Phosphofructokinase Deficiency(PFK) | GTG | ||||
IDIDA |
Âå¼Õ | ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É¡¢CLÉ | CL disease, Ceroid lipofuscinosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¿À·ÐºÙ˦¤ËÏ·ÇÑʪ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥Á¥ó¤òÃßÀѤµ¤»¤ë¿·ÄÄÂå¼Õ¤Î¾ã³²¡£3ºÐÁ°¤Ë»àË´ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
»°É© |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ξÌܤ¬¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA | ||||||
prcd-PRA | GTG | |||||
¿ÕǢϩ¼À´µ | °äÅÁÀ¿Õ¾É | Autosomal Hereditary Recessive Nephropathy(AHRN/FN) | ¥¢¥ë¥Ý¡¼¥È¾É¸õ·²(¿À·ÐÀÆñÄ°¡¦·ìÇ¢¡¦´ã¾É¾õ¤òȼ¤¦°äÅÁÀ¿Ê¹ÔÀ¿Õ±ê)¡¢ÀèÅ·À¥Í¥Õ¥í¡¼¥¼¾É¸õ·²¤Ê¤É¤¤¤¯¤Ä¤«¥¿¥¤¥×¤¬¤¢¤ë¡£1ºÐÁ°¸åº¢¤«¤é¿Õµ¡Ç½°²½¤Î³Æ¼ï¾É¾õ¤¬½Ð»Ï¤á¡¢¿Õ°Ü¿¢¡¦¿Í¹©Æ©ÀϤ¬¸¤¤Ç¤Ï»ö¼Â¾åÉÔ²Äǽ¤Ê¤Î¤ÇÁáǯ¿ÕÉÔÁ´¤Ç»àË´¡£ | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Âå¼Õ | ¦Á-¥Õ¥³¥·¥É¡¼¥·¥¹ | Fucosidosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£¾®¤Ö¤ê¡¢¸Æ¤Ó¤«¤±¤ÎÈ¿±þ¤¬Æߤ¤¡¢¤¤¤Ä¤âÂç¿Í¤·¤¤¡¢¿À·Ð¾ã³²¡¢Æðۤʴé¤Ä¤¡¢¹ü¤ÎÊÑ·Á¡¢´ØÀá¤Î°Û¾ï¡¢Â¿È¯À¹ü°Û¾ï ¥é¥¤¥½¥¾¡¼¥à¼À´µ¤È¤ÏºÙ˦¤ÎÃæ¤ÇÅü¼Á¤äÅü»é¼Á¤Îʬ²ò¤ò¹Ô¤Ã¤Æ¤¤¤ë¥é¥¤¥½¥¾¡¼¥à¤È¸Æ¤ÖÁ´¿È¤Î¤É¤ÎºÙ˦¤Ë¤â¸ºß¤¹¤ë¾®´ï´±(¾®´ï´±¤È¤Ï¡È³Ë¡É¤È¤«¡È¥´¥ë¥¸ÂΡɤȤ«¡È¥ß¥È¥³¥ó¥É¥ê¥¢¡É¤Ê¤É)¤Ç¡¢¹ÚÁǤη绡¦°Û¾ï¤¬µ¯¤³¤êËÜÍèʬ²ò¤µ¤ì¤ë¤Ù¤Êª¼Á¤¬ÃßÀѤ¹¤ë¼À´µ¤ÎÁí¾Î¡£¥Õ¥³¥·¥É¡¼¥·¥¹¤ÏÀèÅ·ÀÂå¼Õ°Û¾ï¤ÎÃæ¤Ç¤âÅü¼ÁÂå¼Õ°Û¾ï |
AR | GTG | »à»º¡¢¿·À¸»ù»àË´ | ¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼·ç»¾É | Phosphofructokinase Deficiency | ¡Ö²òÅü·Ï¹ÚÁǤΣ±¤Ä¤Ç¤¢¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¤Î·ç»¤¬¸¶°ø¤Ç¡¢¿·À¸»ù¤Ç¤ÏÃ×»àÀ¤È¤Ê¤ë¤³¤È¤Î¤¢¤ëɵ¤¤Ç¤¹¡£¡×(¥ê¥Æ¥¤¥ë) ¡ÖÀÖ·ìµå¤ä¶ÚÆù¤Ê¤É¤Ç¥¨¥Í¥ë¥®¡¼¸»¤Ç¤¢¤ë¥°¥ë¥³¡¼¥¹¤ä¥°¥ê¥³¡¼¥²¥ó¤ÎÂå¼Õ¤Ë´Ø¤ï¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¡ÊPFK¡Ë¤Ë°Û¾ï¤¬µ¯¤³¤ëɵ¤¤Ç¤¹¡£¥¨¥Í¥ë¥®¡¼¤¬ÉÔ¤¹¤ë¤³¤È¤Ë¤Ê¤ë¤Î¤Çµõ¼å¡¢¶ÚÆù¤ÎáÛÚ»¡¢²«áÕ¤¬¸«¤é¤ì¤Þ¤¹¡£¡×(¥ê¥ó¥¯¥¹) |
AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
Âå¼Õ | ¥°¥ê¥³¡¼¥²¥óÃù¢É ¡¢Åü¸¶É | Glycogen storage disease | Î¥Æý´üº¢¤«¤éÓÒÅÇ¡¦¥¿¡¼¥ëÍͤβ¼Î¡¡¦¤è¤À¤ì¡¦¶ÚÆù¤¬¼å¤¤¤¿¤áÊâ¹Ôº¤Æñ¡¦¤±¤¤¤ì¤óȯºî¡¦¼º¿À¡¦Âβ¹Äã²¼¤Ê¤É¤ò¼¨¤·½Å¾É¤Î¾ì¹ç¤Ïºª¿ç¡¦¿ê¼å¤·»àË´¤Ë»ê¤ë¡£¾®¤Ö¤ê¡£¿·À¸»ù´ü¤òĶ¤¨¤ë¤ÈÄã·ìÅü¾É¡£·ÚÅ٤ʤâ¤Î¤ÏÄã·ìÅü¾É¤À¤±¤¬ÌÜΩ¤Ä¾ì¹ç¤â¤¢¤ë¡£µðÂç¿©Æ»¾É¡¢¤Æ¤ó¤«¤ó¤ò¹çÊ»¤¹¤ë¤³¤È¤â¤¢¤ë¡£ ´Î¡¤Î¼ç¤ÊƯ¤¤Ï¿©¤Ù¤¿¤â¤Î¤«¤é¥¨¥Í¥ë¥®¡¼¤òºî¤êÃù¢¤¹¤ë¤³¤È¡£Ä²´É¤«¤éµÛ¼ý¤µ¤ì¤¿Ã±ÅüÎà¤Ç¤¢¤ë¥°¥ë¥³¡¼¥¹¡á¥Ö¥É¥¦Åü(À¸ÂΤˤȤäƼçÍפʥ¨¥Í¥ë¥®¡¼¸»)¤ÏÌçÌ®¤òή¤ì¤Æ´Î¡¤Ë±¿¤Ð¤ì¤ë¡£¥°¥ë¥³¡¼¥¹¤ÏÃù¢¤Ë¤Ï¸þ¤¤¤Æ¤¤¤Ê¤¤À¼Á¤ò»ý¤Ã¤Æ¤¤¤ë¤¿¤á´Î¡¤Ï¥°¥ë¥³¡¼¥¹¤«¤é¥°¥ê¥³¡¼¥²¥ó¤È¤¤¤¦Â¿ÅüÎà¤ò¹çÀ®¤·Ãù¢¤¹¤ë¡£Åü¸¶É¤ϥ°¥ê¥³¡¼¥²¥ó¤òʬ²ò¡¦¹çÀ®¤¹¤ë¹ÚÁǤ¬·ç»¤¹¤ë¤¿¤á°Û¾ï¤ËÃßÀѤµ¤ì¤ë¡£ Ä̾ï¤Ï¶õÊ¢¤Ë¤Ê¤ë¤È´Î¡¤ËÃߤ¨¤é¤ì¤Æ¤¤¤ë¥°¥ê¥³¡¼¥²¥ó¤«¤é¥Ö¥É¥¦Åü¤¬ºî¤é¤ì·ìÃæ¤ËÊü½Ð¤µ¤ì¤ë¤¬¡¢¥°¥ê¥³¡¼¥²¥ó¤¬Î±¤Þ¤Ã¤¿¤Þ¤Þ¤À¤È´Î¡¤Î¼ð¤ì¤äÄã·ìÅü¤¬µ¯¤³¤ë¡£¿ÇÃǤ϶ÚÀ¸¸¡ |
AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
¦Á-¥Õ¥³¥·¥É¡¼¥·¥¹ | Fucosidosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£¾®¤Ö¤ê¡¢¸Æ¤Ó¤«¤±¤ÎÈ¿±þ¤¬Æߤ¤¡¢¤¤¤Ä¤âÂç¿Í¤·¤¤¡¢¿À·Ð¾ã³²¡¢Æðۤʴé¤Ä¤¡¢¹ü¤ÎÊÑ·Á¡¢´ØÀá¤Î°Û¾ï¡¢Â¿È¯À¹ü°Û¾ï ¥é¥¤¥½¥¾¡¼¥à¼À´µ¤È¤ÏºÙ˦¤ÎÃæ¤ÇÅü¼Á¤äÅü»é¼Á¤Îʬ²ò¤ò¹Ô¤Ã¤Æ¤¤¤ë¥é¥¤¥½¥¾¡¼¥à¤È¸Æ¤ÖÁ´¿È¤Î¤É¤ÎºÙ˦¤Ë¤â¸ºß¤¹¤ë¾®´ï´±(¾®´ï´±¤È¤Ï¡È³Ë¡É¤È¤«¡È¥´¥ë¥¸ÂΡɤȤ«¡È¥ß¥È¥³¥ó¥É¥ê¥¢¡É¤Ê¤É)¤Ç¡¢¹ÚÁǤη绡¦°Û¾ï¤¬µ¯¤³¤êËÜÍèʬ²ò¤µ¤ì¤ë¤Ù¤Êª¼Á¤¬ÃßÀѤ¹¤ë¼À´µ¤ÎÁí¾Î¡£¥Õ¥³¥·¥É¡¼¥·¥¹¤ÏÀèÅ·ÀÂå¼Õ°Û¾ï¤ÎÃæ¤Ç¤âÅü¼ÁÂå¼Õ°Û¾ï |
AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ | |
IDIDA | ||||||
¥Õ¥³¥·¥É¡¼¥·¥¹ | Fucosidosis(FS) | GTG | ||||
¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼·ç»¾É | Phosphofructokinase Deficiency | ¡Ö²òÅü·Ï¹ÚÁǤΣ±¤Ä¤Ç¤¢¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¤Î·ç»¤¬¸¶°ø¤Ç¡¢¿·À¸»ù¤Ç¤ÏÃ×»àÀ¤È¤Ê¤ë¤³¤È¤Î¤¢¤ëɵ¤¤Ç¤¹¡£¡×(¥ê¥Æ¥¤¥ë) ¡ÖÀÖ·ìµå¤ä¶ÚÆù¤Ê¤É¤Ç¥¨¥Í¥ë¥®¡¼¸»¤Ç¤¢¤ë¥°¥ë¥³¡¼¥¹¤ä¥°¥ê¥³¡¼¥²¥ó¤ÎÂå¼Õ¤Ë´Ø¤ï¤ë¥Õ¥©¥¹¥Õ¥©¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼¡ÊPFK¡Ë¤Ë°Û¾ï¤¬µ¯¤³¤ëɵ¤¤Ç¤¹¡£¥¨¥Í¥ë¥®¡¼¤¬ÉÔ¤¹¤ë¤³¤È¤Ë¤Ê¤ë¤Î¤Çµõ¼å¡¢¶ÚÆù¤ÎáÛÚ»¡¢²«áÕ¤¬¸«¤é¤ì¤Þ¤¹¡£¡×(¥ê¥ó¥¯¥¹) |
AR | ¥ê¥Æ¥¤¥ë | »à»º¡¢¿·À¸»ù»àË´ | |
»°É© | ||||||
¥Û¥¹¥Û¥Õ¥ë¥¯¥È¥¥Ê¡¼¥¼·ç»¾É | Phosphofructokinase Deficiency(PFK) | GTG | ||||
IDIDA | ||||||
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Cord1-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | »°É© | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
Âå¼Õ | ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É¡¢CLÉ | CL disease, Ceroid lipofuscinosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¿À·ÐºÙ˦¤ËÏ·ÇÑʪ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥Á¥ó¤òÃßÀѤµ¤»¤ë¿·ÄÄÂå¼Õ¤Î¾ã³²¡£3ºÐÁ°¤Ë»àË´ | AR | ¥Ð¥¤¥ª¥¹ | CLN8°äÅÁ»Ò |
¥«¥Û¥Æ¥¯¥Î | ||||||
¥À¡¼¥¦¥£¥ó | ||||||
IDIDA | ||||||
»°É© |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA |
Âå¼Õ | ¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼·ç»¾É | Pyruvate kinase Deficiency | ¥Ø¥â¥°¥í¥Ó¥ó·ì¾É¡¢¥Ø¥â¥°¥í¥Ó¥óÇ¢¾É(øÀÖ¿§¤«¤é°ÅÀÖ¿§¤ÎÇ¢¡£·ìÇ¢¤È¤Î¶èÊ̤ÏÆ©ÌÀ´¶¤¬¤¢¤ë¡¢ÀÅÃÖ¤·¤Æ¤âÃ忧ÁؤÈÈóÃ忧ÁؤËʬ¤«¤ì¤Ê¤¤¡¢¸²Èù¶À²¼¤ÇÀÖ·ìµå¤¬¸«¤é¤ì¤Ê¤¤¤Ê¤É)¡¢È¯Ç®¡¢¿ê¼å¡£ÍÏ·ìÀÉÏ·ì(ÀÖ·ìµåÆâ¤Î¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼¤È¤¤¤¦¹ÚÁǤ¬Ãø¤·¤¯³èÀÄã²¼¤¹¤ë¤³¤È¤Ë¤è¤Ã¤ÆÀÖ·ìµå¤Î¼÷Ì¿¤¬Ã»½Ì¤·ÍÏ·ìÀÉÏ·ì¤ò°ú¤µ¯¤³¤¹¡£·ì´ÉÆâÍÏ·ì¡£)°ìÅÙ¤ËÂçÎ̤ÎÀÖ·ìµå¤¬Ç˲õ¤µ¤ì¤ë¤ÈÄã»ÀÁǾɤ«¤é¥·¥ç¥Ã¥¯¡¢Â¡´ï(¤È¤¯¤Ë¿Õ¡)ÉÔÁ´¡£ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ ¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼(PK)¤Ï¤Û¤È¤ó¤É¤ÎÀ¸Êª¤Ë¸ºß¤¹¤ë¹ÚÁÇ¡£ ¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼·ç˳¤Ë¤è¤Ã¤Æ¥Þ¥é¥ê¥¢Äñ¹³À¤¬¤â¤¿¤é¤µ¤ì¤ë¤³¤È¤¬¥Þ¥¦¥¹¤Î¸¦µæ¤Ç¼¨¤µ¤ì¤Æ¤¤¤ë¡£Bio Today¤Î08/04/17¤Îµ»ö¤è¤ê Hb¡á¥Ø¥â¥°¥í¥Ó¥ó¡á·ì¿§ÁÇ(¤±¤Ã¤·¤¤½)¤È¤Ï¹ÚÁǤò±¿È¤¹¤ëµ¡Ç½¤Î¤¢¤ëÀÖ·ìµåÃæ¤Ë¸ºß¤¹¤ëÀÖ¿§¤Î¿§ÁÇ¥¿¥ó¥Ñ¥¯¡£ ¥Õ¥£¥é¥ê¥¢¾É¤Ç¤âƱ¾É¾õ¤È¤Ê¤ë¡£ |
IDIDA | ||||||
»°É© |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ξÌܤ¬¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¥ê¥Æ¥¤¥ë | ||||||
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
»°É© | ||||||
rcd3¿Ê¹ÔÀÌÖËì°à½Ì¾É | rcd3-PRA | GTG | ||||
Ì鱅 | ½Å¾ÉÊ£¹çÌȱÖÉÔÁ´¾É | Severe combined immunodeficiency | ¥ï¥¯¥Á¥óÀܼï¸ÄÂΤǤâÅÁÀ÷ɤˤè¤êÀ¸¸å6¤«·î¤³¤í¤Þ¤Ç¤Ë»àË´¡£TºÙ˦¤Î·ç»¤«¤ÄBºÙ˦¤Î·ç»¤Þ¤¿¤Ïµ¡Ç½°Û¾ï¤Ë¤è¤ë¡¢±ÕÀ¡¦ºÙ˦ÀÌȱÖǽ¤Î¡Ê¤Û¤Ü´°Á´¤Ê¡Ë·çÇ¡¤Ç¤¢¤ë¡£À¸¸å¿ôÆü°ÊÆ⤫¤éǧ¤á¤é¤ì¤ëÈ¿Éü´¶À÷¡¢²¼Î¡¡¢À®Ä¹¾ã³²¡¢ºÙ¶Ý¡¦¿¿¶Ý¡¦¥¦¥¤¥ë¥¹¤¹¤Ù¤Æ¤Îɸ¶ÂΤËÂФ¹¤ë°×´¶À÷À¤ò¼¨¤¹¡£¸¤¤Ç¤Ï¸½¼ÂŪ¤Ë¤·ì´´ºÙ˦°Ü¿¢¤Ê¤É¤Î¼£ÎŤ¬¤Ç¤¤Ê¤¤¤¿¤áÁá´ü¤Ë»àË´¤¹¤ë½ÅÆƤʼÀ´µ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´¡¡ |
IDIDA |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ,¶,· | GTG | |||||
Von Willebrand's Disease(vWD)Typeµ | »°É© |
·ì±Õ | Âè»°ø»Ò·ç˳¾É | *** | *** | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | CEA, Collie eye anomaly | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ¸¸å2¥õ·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
GTG | ||||||
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ | |
°äÅÁÀÇòÆâ¾ã | Cataracts | ¿å¾½ÂΤÎÇòÂù¡£Ï·ÎðÀ¡¢ÅüÇ¢ÉÂÀ¡¢³°½ýÀ¡¢ÆâʬÈçÀ¡¢ÃæÆÇÀ¤Î¸åÅ·À¤Î¤â¤Î¤È¼ãǯÀ(Ìܰ¤Ȥ·¤Æ6ºÐ°ÊÁ°)¡£¼ºÌÀ¡£PRA¤Î¹çÊ»¾É¤È¤·¤Æ¤â¸½¤ì¤ë¡£¿Ê¹ÔÅٹ礤¤¬µÞ¤Ç¤¢¤ì¤ÐÅüǢɤ⵿¤¨¤ë¡£Áá´üȯ¸«¤Ç¤¤¿¤éÆâÉþÌô¤ÈÅÀ´ãÌô¤Ç¿Ê¹Ô¤òÃ٤餻¤ë¼£ÎŤ¬¤Ç¤¤ë¾ì¹ç¤â¿¤¤¡£ | AR? | GTG | ||
Âå¼Õ | ¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǾɡ¢MDR1·ç» | Ivermectinsensitivity | ¥Õ¥£¥é¥ê¥¢¤ÎͽËÉÌô¤Ê¤É¤Î¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ê¤É¿ô¼ï¤ÎÌô¤Ë²áÉÒ¡¢ÓÒÅÇ¡¦¤±¤¤¤ì¤ó¡¦¿Ì¤¨¡¦¤è¤À¤ì¡¦±¿Æ°¼ºÄ´¡¦¤Æ¤ó¤«¤óÍÍȯºî¤Ê¤É¡£½ÅÅ٤ϻàË´ | AR | ¥Ð¥¤¥ª¥¹ | |
¥¢¥É¥Æ¥Ã¥¯ | ||||||
IDIDA | ||||||
Ivermectin Sensitive MDR1(IVM) | GTG | |||||
¶Ú¹ü³Ê | ¥Ê¥Á¥å¥é¥ë¥Ü¥Ö¥Æ¡¼¥ëÀèÅ·ÀûÈø | * | ÀèŷŪ¤ËÈø¹ü¤¬Ã»¤¤Éµ¤¤Ç¤¹¡£Í¥À¥Û¥â·ë¹ç¤Î¾ì¹ç¡¢¤½¤Î»Ò¸¤¤ÏÀ¸¤±ä¤Ó¤ë¤³¤È¤¬¤Ç¤¤Þ¤»¤ó(GTG) | AR? | GTG |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£
|
¶Ú¹ü³Ê | ¥Ê¥Á¥å¥é¥ë¥Ü¥Ö¥Æ¡¼¥ëÀèÅ·ÀûÈø | * | ÀèŷŪ¤ËÈø¹ü¤¬Ã»¤¤Éµ¤¤Ç¤¹¡£Í¥À¥Û¥â·ë¹ç¤Î¾ì¹ç¡¢¤½¤Î»Ò¸¤¤ÏÀ¸¤±ä¤Ó¤ë¤³¤È¤¬¤Ç¤¤Þ¤»¤ó(GTG) | AR? | GTG |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ,¶,· | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
Âå¼Õ | ¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǾɡ¢MDR1·ç» | Ivermectin Sensitive MDR1(IVM) | ¥Õ¥£¥é¥ê¥¢¤ÎͽËÉÌô¤Ê¤É¤Î¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ê¤É¿ô¼ï¤ÎÌô¤Ë²áÉÒ¡¢ÓÒÅÇ¡¦¤±¤¤¤ì¤ó¡¦¿Ì¤¨¡¦¤è¤À¤ì¡¦±¿Æ°¼ºÄ´¡¦¤Æ¤ó¤«¤óÍÍȯºî¤Ê¤É¡£½ÅÅ٤ϻàË´ | AR | GTG |
Âå¼Õ | ¥Ô¥ë¥Ó¥ó»Àæ¿åÁǹÚÁÇ¥Û¥¹¥Õ¥¡¥¿¡¼¥¼·ç»¾É | Pyruvate Dehydrogenase Phosphatase Deficiency | Æý»À¤ÎÃßÀѤˤè¤ë¶ÚÎÏÄã²¼¡¢´Î¾ã³²¡¢¤±¤¤¤ì¤óȯºî¡¢ATP(¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»À)»ºÀ¸Äã²¼¡¢ÀÖ·ìµåÆâæ¿å¡¢ç£¼ð¡£PK·ç»¾É¡£±¿Æ°¤ä´¶À÷¾É¤Ç°²½¡¢¥Ò¥È¤Î¾ì¹ç¤Ï´Î¡¤Þ¤¿¤ÏÈéÉæ¤ÎºÙ˦¤Î¹ÚÁdzèÀ¤ò¬Äꤹ¤ë¤³¤È¤Ç¿ÇÃÇ(Ëö¾¿·ìɸËܤÇÍÛùÀÖ·ìµå¤¬¸«¤é¤ì¤ë)¡¢¼£ÎŤÏç£Â¡Å¦½Ð | AR | GTG |
»à»º¡¢¿·À¸»ù»àË´ ¥Ô¥ë¥Ó¥ó»À¤È¤Ï¼ï¡¹¤ÎÂå¼Õ·Ï¤Ë´ØÍ¿¤·¤Æ¤¤¤ë½ÅÍפÊÌò³ä¤Î¹ÚÁÇ¡£¤Û¤ÜÁ´¤Æ¤Î¹ÚÁǤηç˳¤¬ÀèÅ·ÀÍÏ·ìÀÉÏ·ì¤È´Ø·¸¤¹¤ë¡£ |
¥Ô¥ë¥Ó¥ó»À¥«¥ë¥Ü¥¥·¥·¥é¡¼¥¼¥¼·ç»¾É | Pyruvate ?? Deficiency | * | * | »°É© | * |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ,¶,· | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | IDIDA | »à»º¡¢¿·À¸»ù»àË´ |
Von Willebrand's Disease(vWD)Type· | »°É© |
Âå¼Õ | XÀ÷¿§ÂÎÏ¢º¿¶Ú¥¸¥¹¥È¥í¥Õ¥£¡¼ | X-linked muscular dystrophy | ¶ÚÆù¤Î°à½Ì¡¢ÊâÍͰ۾¶ÚÎϤÎÄã²¼¤«¤é¿´¶Ú¤ä¸ÆµÛ¤Î¤¿¤á¤Î¶ÚÆù¤Ë¤â¾ã³²¤¬µ¯¤³¤ê¿´ÉÔÁ´¤ä¸ÆµÛº¤Æñ¤Ç»àË´ | X-link | ¥Ð¥¤¥ª¥¹ ¸¡ºº¤Ï¥á¥¹¤Î¤ß |
|
IDIDA |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | CEA, Collie eye anomaly | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ®¸ì¤«·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
Collie Eye Anomaly(CEA/CH) | GTG | |||||
Âå¼Õ | ¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǾɡ¢MDR1·ç» | Ivermectinsensitivity | ¥Õ¥£¥é¥ê¥¢¤ÎͽËÉÌô¤Ê¤É¤Î¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ê¤É¿ô¼ï¤ÎÌô¤Ë²áÉÒ¡¢ÓÒÅÇ¡¦¤±¤¤¤ì¤ó¡¦¿Ì¤¨¡¦¤è¤À¤ì¡¦±¿Æ°¼ºÄ´¡¦¤Æ¤ó¤«¤óÍÍȯºî¤Ê¤É¡£½ÅÅ٤ϻàË´ | AR | ¥Ð¥¤¥ª¥¹ | |
¥¢¥É¥Æ¥Ã¥¯ | ||||||
IDIDA | ||||||
Ivermectin Sensitive MDR1(IVM) | GTG | |||||
·ì±Õ | ¼þ´üÀ¹¥Ãæµå¸º¾¯¾É/¥°¥ì¡¼¥³¥ê¡¼¾É¸õ·² | Cyclic neutropenia/Gray collie syndrome | 10Æü¡Á¼þ´üŪ¤Ë·«¤êÊÖ¤¹È¯Ç®¡¢¸ý¹ÐÆâÄÙáç¡¢ÈéÉæ´¶À÷¾É | AR | IDIDA |
¹¥Ãæµå¤ÏÇò·ìµå¤Î¹½À®À®Ê¬¤Ç¡¢¼ç¤ËºÙ¶Ý¤ä¿¿¶Ý¤ËÂФ·¤Æ´¶À÷¤òËɤ° |
»°É© | ||||||
¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Type¶ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
|
ÌÓ¿§ | ¥À¥Ã¥×¥ë¡¢¥Þ¡¼¥ë | Dapple/Merle | Í¥À¤ÎÌÓ¿§°äÅÁ»Ò¤ÇÍ¥ÀM¤ÏȾÃ×»à°äÅÁ»Ò¡¢MM¥Û¥âÀܹç¤Ç¤Ï¹â¤¤³ÎΨ¤ÇÃ×̿Ū¤È¤Ê¤ë¡£ÌӤ理äÊÁ¤À¤±¤Ç¤Ê¤¯ÂÛÆâ¤Çȯ㤹¤ëºÝ¿À·ÐÄéºÙ˦¤Ë°Û¾ï¤ÊƯ¤¤«¤±¤ò¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¥«¥é¡¼¤Ø¤Î±Æ¶Á¤À¤±¤Ç¤Ê¤¯¡¢µõ¼å¡¢Ä°³Ð¾ã³²¡¦¾®´ã¾É¡¦´ã°µ¾å¾º¡¦¼å»ë¡¢¿À·Ð°Û¾ï¤òµ¯¤³¤¹¡£ ¥·¥ó¥°¥ë¥Þ¡¼¥ë¤Î37%¤ËÆñÄ°¡¦¿§³Ð°Û¾ï(·ÚÅÙ¡Á½ÅÅÙ¤Þ¤ÇÍÍ¡¹¤À¤È»×¤ï¤ì¤ë)¤ò¼¨¤¹¤È¤Î¸¦µæ·ë²Ì¤â¤¢¤ë |
AD | ¥Ð¥¤¥ª¥¹ | ¥À¥Ã¥×¥ë(¥Þ¡¼¥ë)¤Îȯ¸½ÌÌÀѤϥé¥ó¥À¥à¤Ê¤¿¤á¡¢¸ÄÂΤˤè¤Ã¤Æ¤Ï¸«Íî¤È¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ç¤³¤Î¸¡ºº¤Ï¥»¡¼¥Ö¥ë¥Þ¡¼¥ë¤Ë¤è¤ê͸ú¤È»×¤ï¤ì¤ë¤¬¡¢¥Þ¡¼¥ë¤«¤é»º¤Þ¤ì¤¿¥È¥é¥¤¤ä¥Ð¥¤¥«¥é¡¼¤âÈË¿£ÍÑÅӤǤ¢¤ì¤Ð¤ª¤³¤Ê¤Ã¤Æ¤ß¤ë²ÁÃͤϤ¢¤ë |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | CEA, Collie eye anomaly | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ®¸ì¤«·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
Collie Eye Anomaly(CEA/CH) | GTG | |||||
Âå¼Õ | ¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǾɡ¢MDR1·ç» | Ivermectinsensitivity | ¥Õ¥£¥é¥ê¥¢¤ÎͽËÉÌô¤Ê¤É¤Î¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ê¤É¿ô¼ï¤ÎÌô¤Ë²áÉÒ¡¢ÓÒÅÇ¡¦¤±¤¤¤ì¤ó¡¦¿Ì¤¨¡¦¤è¤À¤ì¡¦±¿Æ°¼ºÄ´¡¦¤Æ¤ó¤«¤óÍÍȯºî¤Ê¤É¡£½ÅÅ٤ϻàË´ | AR | ¥Ð¥¤¥ª¥¹ | |
¥¢¥É¥Æ¥Ã¥¯ | ||||||
IDIDA | ||||||
·ì±Õ | ¼þ´üÀ¹¥Ãæµå¸º¾¯¾É/¥°¥ì¡¼¥³¥ê¡¼¾É¸õ·² | Cyclic neutropenia/Gray collie syndrome | 10Æü¡Á¼þ´üŪ¤Ë·«¤êÊÖ¤¹È¯Ç®¡¢¸ý¹ÐÆâÄÙáç¡¢ÈéÉæ´¶À÷¾É | AR | IDIDA | ¹¥Ãæµå¤ÏÇò·ìµå¤Î¹½À®À®Ê¬¤Ç¡¢¼ç¤ËºÙ¶Ý¤ä¿¿¶Ý¤ËÂФ·¤Æ´¶À÷¤òËɤ° |
»°É© | ||||||
¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Type¶ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
|
ÌÓ¿§ | ¥À¥Ã¥×¥ë¡¢¥Þ¡¼¥ë | Dapple/Merle | Í¥À¤ÎÌÓ¿§°äÅÁ»Ò¤ÇÍ¥ÀM¤ÏȾÃ×»à°äÅÁ»Ò¡¢MM¥Û¥âÀܹç¤Ç¤Ï¹â¤¤³ÎΨ¤ÇÃ×̿Ū¤È¤Ê¤ë¡£ÌӤ理äÊÁ¤À¤±¤Ç¤Ê¤¯ÂÛÆâ¤Çȯ㤹¤ëºÝ¿À·ÐÄéºÙ˦¤Ë°Û¾ï¤ÊƯ¤¤«¤±¤ò¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¥«¥é¡¼¤Ø¤Î±Æ¶Á¤À¤±¤Ç¤Ê¤¯¡¢µõ¼å¡¢Ä°³Ð¾ã³²¡¦¾®´ã¾É¡¦´ã°µ¾å¾º¡¦¼å»ë¡¢¿À·Ð°Û¾ï¤òµ¯¤³¤¹¡£ ¥·¥ó¥°¥ë¥Þ¡¼¥ë¤Î37%¤ËÆñÄ°¡¦¿§³Ð°Û¾ï(·ÚÅÙ¡Á½ÅÅÙ¤Þ¤ÇÍÍ¡¹¤À¤È»×¤ï¤ì¤ë)¤ò¼¨¤¹¤È¤Î¸¦µæ·ë²Ì¤â¤¢¤ë |
AD | ¥Ð¥¤¥ª¥¹ | ¥À¥Ã¥×¥ë(¥Þ¡¼¥ë)¤Îȯ¸½ÌÌÀѤϥé¥ó¥À¥à¤Ê¤¿¤á¡¢¸ÄÂΤˤè¤Ã¤Æ¤Ï¸«Íî¤È¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ç¤³¤Î¸¡ºº¤Ï¥»¡¼¥Ö¥ë¥Þ¡¼¥ë¤Ë¤è¤ê͸ú¤È»×¤ï¤ì¤ë¤¬¡¢¥Þ¡¼¥ë¤«¤é»º¤Þ¤ì¤¿¥È¥é¥¤¤ä¥Ð¥¤¥«¥é¡¼¤âÈË¿£ÍÑÅӤǤ¢¤ì¤Ð¤ª¤³¤Ê¤Ã¤Æ¤ß¤ë²ÁÃͤϤ¢¤ë |
Âå¼Õ | ¥Ô¥ë¥Ó¥ó»Àæ¿åÁǹÚÁÇ¥Û¥¹¥Õ¥¡¥¿¡¼¥¼·ç»¾É | Pyruvate Dehydrogenase Phosphatase Deficiency | Æý»À¤ÎÃßÀѤˤè¤ë¶ÚÎÏÄã²¼¡¢´Î¾ã³²¡¢¤±¤¤¤ì¤óȯºî¡¢ATP(¥¢¥Ç¥Î¥·¥ó»°¥ê¥ó»À)»ºÀ¸Äã²¼¡¢ÀÖ·ìµåÆâæ¿å¡¢ç£¼ð¡£PK·ç»¾É¡£±¿Æ°¤ä´¶À÷¾É¤Ç°²½¡¢¥Ò¥È¤Î¾ì¹ç¤Ï´Î¡¤Þ¤¿¤ÏÈéÉæ¤ÎºÙ˦¤Î¹ÚÁdzèÀ¤ò¬Äꤹ¤ë¤³¤È¤Ç¿ÇÃÇ(Ëö¾¿·ìɸËܤÇÍÛùÀÖ·ìµå¤¬¸«¤é¤ì¤ë)¡¢¼£ÎŤÏç£Â¡Å¦½Ð | AR | GTG |
»à»º¡¢¿·À¸»ù»àË´ ¥Ô¥ë¥Ó¥ó»À¤È¤Ï¼ï¡¹¤ÎÂå¼Õ·Ï¤Ë´ØÍ¿¤·¤Æ¤¤¤ë½ÅÍפÊÌò³ä¤Î¹ÚÁÇ¡£¤Û¤ÜÁ´¤Æ¤Î¹ÚÁǤηç˳¤¬ÀèÅ·ÀÍÏ·ìÀÉÏ·ì¤È´Ø·¸¤¹¤ë¡£ |
¥Ô¥ë¥Ó¥ó»À¥«¥ë¥Ü¥¥·¥·¥é¡¼¥¼¥¼·ç»¾É | Pyruvate ?? Deficiency | * | * | »°É© | * |
ÌÜ | XÏ¢º¿¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | XL-PRA | ξÌܤ¬¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | X-Link | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¿ÕǢϩ¼À´µ | ÀèÅ·À¿Õ¾É | Hereditary Nephritis | ¥¢¥ë¥Ý¡¼¥È¾É¸õ·²(¿À·ÐÀÆñÄ°¡¦·ìÇ¢¡¦´ã¾É¾õ¤òȼ¤¦°äÅÁÀ¿Ê¹ÔÀ¿Õ±ê)¡¢ÀèÅ·À¥Í¥Õ¥í¡¼¥¼¾É¸õ·²¤Ê¤É¤¤¤¯¤Ä¤«¥¿¥¤¥×¤¬¤¢¤ë¡£1ºÐÁ°¸åº¢¤«¤é¿Õµ¡Ç½°²½¤Î³Æ¼ï¾É¾õ¤¬½Ð»Ï¤á¡¢¿Õ°Ü¿¢¡¦¿Í¹©Æ©ÀϤ¬¸¤¤Ç¤Ï»ö¼Â¾åÉÔ²Äǽ¤Ê¤Î¤ÇÁáǯ¿ÕÉÔÁ´¤Ç»àË´¡£ | * | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | CEA, Collie eye anomaly | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ®¸ì¤«·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
Collie Eye Anomaly(CEA/CH) | GTG | |||||
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ,¶,· | GTG | |||||
Von Willebrand's Disease(vWD)Type· | »°É© | |||||
Âå¼Õ | ¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǾɡ¢MDR1·ç» | Ivermectinsensitivity | ¥Õ¥£¥é¥ê¥¢¤ÎͽËÉÌô¤Ê¤É¤Î¥¤¥Ù¥ë¥á¥¯¥Á¥ó¤Ê¤É¿ô¼ï¤ÎÌô¤Ë²áÉÒ¡¢ÓÒÅÇ¡¦¤±¤¤¤ì¤ó¡¦¿Ì¤¨¡¦¤è¤À¤ì¡¦±¿Æ°¼ºÄ´¡¦¤Æ¤ó¤«¤óÍÍȯºî¤Ê¤É¡£½ÅÅ٤ϻàË´ | AR | ¥Ð¥¤¥ª¥¹ |
¡¦¤è¤Ä¤Ð¤È¤«¡¼¤Á¤ã¤óÍÍ¡Ö¥¤¥Ù¥ë¥á¥¯¥Á¥óÃæÆǤˤĤ¤¤ÆÄ´¤Ù¤Æ¤ß¤¿¡× http://blogs.yahoo.co.jp/ yotsuba1030/19765946.html |
¥¢¥É¥Æ¥Ã¥¯ | ||||||
IDIDA | ||||||
Ivermectin Sensitive MDR1(IVM) | GTG |
Âå¼Õ | GM1 ¥¬¥ó¥°¥ê¥ª¥·¥É¡¼¥·¥¹ | GM1 Gangliosidosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¦Â-galactosidase¤Î·ç»¤Ë¤è¤êÃæ¿õ¿À·Ð·Ï¤ËGM1¥¬¥ó¥°¥ê¥ª¥·¥É¡¢¹ü¤ò´Þ¤àÁ´¿È¡´ï¤Ë¥±¥é¥¿¥óβ»À¡¢¥ª¥ê¥´Åü¤ÎÃßÀѤ¬µ¯¤³¤ë¡£¹üÊÑ·Á¤ä´Î磼ð¤ä¿íÂÎÏ©¾ã³²¡¢´ãÄì¤Ëcherry red spot¤¬¤ß¤é¤ì¤ë¤Ê¤É | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ξÌܤοʹÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£
|
IDIDA | ||||||
XÏ¢º¿¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | XL-PRA | X-Link | GTG |
¤¬¤ó | ¿Õǹ˦Á£´â/·ëÀáÀÈéÉæÀþ°Ý¾É | Renal cystadenocarcinoma/Nobular dermatofibrosis | ¤Û¤È¤ó¤É¤¬Ìµ¾É¾õ¤Î¤Þ¤Þ¿Õ¡Á´ÂΤËǹ˦¤¬È¯À¸¤·¿Ê¹ÔÀ¤Î¿ÕÉÔÁ´¤È¤Ê¤ë¡£´Î磼𡢤ޤì¤ËÄˤߤä·ìÇ¢¡¢È¯Ç®¤Ê¤É¡£Ç¹Ë¦¤È¤ÏÉÂŪ¤Ë·ÁÀ®¤µ¤ì¤¿ÂÞ¾õ¤Î·ÁÂÖ ÈéÉæÀþ°Ý¾É?? |
AR,AD | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
»°É© |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
von Willebrans's disease Type¶ | »°É© | ¥í¥ó¥°¡¢¥ï¥¤¥¢¡¼¤â | ||||
ÌÜ | ÌÖËì¿íÂÎÊÑÀ¾É | Cone Degeneration(CD) | ¿Ê¹ÔÀ¤ÎÌëÌÕ¡¢»ëÌºõ¡¢»ëÎÏÄã²¼¡£¼ãǯÀÇòÆâ¾ã¤äÎÐÆâ¾ã¤òʻȯ¤¹¤ë¥±¡¼¥¹¤â¿¤¤¡£´ãÄ쿧ÁÇÄÀÃå¡¢»ë¿À·Ð¤Î°à½Ì¤¬¸«¤é¤ì¤ë¤³¤È¤â¤¢¤ë¡£ | AR,AD,X-Link | GTG |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
·ì±Õ | Âè»°ø»Ò·ç˳¾É | * | * | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
Ì鱅 | ½Å¾ÉÊ£¹çÌȱÖÉÔÁ´¾É | Severe combined immunodeficiency | ¥ï¥¯¥Á¥óÀܼï¸ÄÂΤǤâÅÁÀ÷ɤˤè¤êÀ¸¸å6¤«·î¤³¤í¤Þ¤Ç¤Ë»àË´¡£TºÙ˦¤Î·ç»¤«¤ÄBºÙ˦¤Î·ç»¤Þ¤¿¤Ïµ¡Ç½°Û¾ï¤Ë¤è¤ë¡¢±ÕÀ¡¦ºÙ˦ÀÌȱÖǽ¤Î¡Ê¤Û¤Ü´°Á´¤Ê¡Ë·çÇ¡¤Ç¤¢¤ë¡£À¸¸å¿ôÆü°ÊÆ⤫¤éǧ¤á¤é¤ì¤ëÈ¿Éü´¶À÷¡¢²¼Î¡¡¢À®Ä¹¾ã³²¡¢ºÙ¶Ý¡¦¿¿¶Ý¡¦¥¦¥¤¥ë¥¹¤¹¤Ù¤Æ¤Îɸ¶ÂΤËÂФ¹¤ë°×´¶À÷À¤ò¼¨¤¹¡£¸¤¤Ç¤Ï¸½¼ÂŪ¤Ë¤·ì´´ºÙ˦°Ü¿¢¤Ê¤É¤Î¼£ÎŤ¬¤Ç¤¤Ê¤¤¤¿¤áÁá´ü¤Ë»àË´¤¹¤ë½ÅÆƤʼÀ´µ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
·ì±Õ | Âè»°ø»Ò·ç˳¾É | * | * | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
¥ê¥Æ¥¤¥ë | ||||||
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ,¶,· | GTG | |||||
Von Willebrand's Disease(vWD)Type· | »°É© |
ÌÜ | °äÅÁÀÇòÆâ¾ã | Cataracts | ¿å¾½ÂΤÎÇòÂù¡£Ï·ÎðÀ¡¢ÅüÇ¢ÉÂÀ¡¢³°½ýÀ¡¢ÆâʬÈçÀ¡¢ÃæÆÇÀ¤Î¸åÅ·À¤Î¤â¤Î¤È¼ãǯÀ(Ìܰ¤Ȥ·¤Æ6ºÐ°ÊÁ°)¡£¼ºÌÀ¡£PRA¤Î¹çÊ»¾É¤È¤·¤Æ¤â¸½¤ì¤ë¡£¿Ê¹ÔÅٹ礤¤¬µÞ¤Ç¤¢¤ì¤ÐÅüǢɤ⵿¤¨¤ë¡£Áá´üȯ¸«¤Ç¤¤¿¤éÆâÉþÌô¤ÈÅÀ´ãÌô¤Ç¿Ê¹Ô¤òÃ٤餻¤ë¼£ÎŤ¬¤Ç¤¤ë¾ì¹ç¤â¿¤¤¡£ | AD | IDIDA | |
»°É© |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ,¶,· | GTG | |||||
Ǿ¿À·Ð | ¿·À¸»ùǾ¾É | * | * | AR | »°É© | * |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ξÌܤ¬¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ξÌܤοʹÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA | ||||||
rcd1a¿Ê¹ÔÀÌÖËì°à½Ì¾É | rcd1a-PRA | GTG |
Âå¼Õ | ¥à¥³Â¿Åü¾É ¥¿¥¤¥×IIIA | Mucopolysaccharidosis type IIIA | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¡£È¯°é¾ã³²¡¢¤±¤¤¤ì¤óȯºî¡¢Êâ¹Ôº¤Æñ¡¢¼ªÉ¡¼À´µ¡¢¿ç̲¾ã³²¡¢¥à¥³Â¿Åüʬ²ò¹ÚÁǤη绤ˤè¤êÃßÀѤµ¤ìÃæ¿õ¿À·Ð¤ËͳÍ褹¤ëÍÍ¡¹¤Ê½ÅÅپ㳲¤òµ¯¤³¤¹¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
Ǿ¿À·Ð | ȯºîÀ¿ç̲¡¢¥Ê¥ë¥³¥ì¥×¥·¡¼ | Narcolepsy | ´¶¾ð¤¬¹â¤Þ¤Ã¤¿ºÝ(¤ª¤ä¤Ä¤ò¿©¤Ù¤ë»þ¡¢»¶Êâ¤Ë½Ðȯ¤¹¤ë»þ¤Ê¤É)¤Ë¿ôÉáÁ¿ô½½ÉäÎæÎÏȯºî¤¬µ¯¤³¤ë¡£È¯ºî¤ÏÄ̾ïÀ¸Ì¿¤Î´íµ¡¤Ï̵¤¤¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
GTG | ||||||
IDIDA |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | GTG | ||||
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Type¶ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤È¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | GTG | ||||
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ,¶,· | GTG | |||||
Von Willebrand's Disease(vWD)Typeµ | »°É© | |||||
Ǿ¿À·Ð | ȯºîÀ¿ç̲¡¢¥Ê¥ë¥³¥ì¥×¥·¡¼ | Narcolepsy | ´¶¾ð¤¬¹â¤Þ¤Ã¤¿ºÝ(¤ª¤ä¤Ä¤ò¿©¤Ù¤ë»þ¡¢»¶Êâ¤Ë½Ðȯ¤¹¤ë»þ¤Ê¤É)¤Ë¿ôÉáÁ¿ô½½ÉäÎæÎÏȯºî¤¬µ¯¤³¤ë¡£È¯ºî¤ÏÄ̾ïÀ¸Ì¿¤Î´íµ¡¤Ï̵¤¤¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
GTG | ||||||
IDIDA |
¿ÕǢϩ¼À´µ | ¥·¥¹¥Á¥óÇ¢¾É | Cystinuria | ºÆµÛ¼ý¤µ¤ì¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¥·¥¹¥Á¥ó¤È¤¤¤¦¤¿¤ó¤Ñ¤¯¼Á¤¬Ç¢¤Ë½Ð¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤Ã¤Æ·ëÀФ¬ºî¤é¤ì¤ë¡£Ç¢¤Îph¤Ï°Û¤Ê¤ë¤¬¡¢¥¹¥È¥ë¥Ð¥¤¥È·ëÀФòʻȯ¤¹¤ë¤³¤È¤â¤¢¤ê¡¢¥¹¥È¥ë¥Ð¥¤¥È¤Î¼£ÎŤ¬¤¦¤Þ¤¯¿Ê¤Þ¤Ê¤¤»þ¤Ïµ¿¤¨¤ë¡£¥Û¥âÀܹç¤Î¾ì¹ç¤Ï·ëÀФȤʤ뤬¡¢¥Ø¥Æ¥í¤Ç¤Ï·ëÀФϷÁÀ®¤µ¤ì¤Ê¤¤¤¬Ä̾ï¤è¤ê¿¤¤¥·¥¹¥Á¥ó¤¬ÇӽФµ¤ì¤Æ¤¤¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
»°É© | ||||||
Cystinuria(CYN) | GTG |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | Collie Eye Anomaly(CEA/CH) | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ®¸ì¤«·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | GTG | |
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ,¶,· | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Von Willebrand's Disease(vWD)Typeµ | »°É© |
Ì鱅 | ½Å¾ÉÊ£¹çÌȱÖÉÔÁ´¾É | Severe combined immunodeficiency | ¥ï¥¯¥Á¥óÀܼï¸ÄÂΤǤâÅÁÀ÷ɤˤè¤êÀ¸¸å6¤«·î¤³¤í¤Þ¤Ç¤Ë»àË´¡£TºÙ˦¤Î·ç»¤«¤ÄBºÙ˦¤Î·ç»¤Þ¤¿¤Ïµ¡Ç½°Û¾ï¤Ë¤è¤ë¡¢±ÕÀ¡¦ºÙ˦ÀÌȱÖǽ¤Î¡Ê¤Û¤Ü´°Á´¤Ê¡Ë·çÇ¡¤Ç¤¢¤ë¡£À¸¸å¿ôÆü°ÊÆ⤫¤éǧ¤á¤é¤ì¤ëÈ¿Éü´¶À÷¡¢²¼Î¡¡¢À®Ä¹¾ã³²¡¢ºÙ¶Ý¡¦¿¿¶Ý¡¦¥¦¥¤¥ë¥¹¤¹¤Ù¤Æ¤Îɸ¶ÂΤËÂФ¹¤ë°×´¶À÷À¤ò¼¨¤¹¡£¸¤¤Ç¤Ï¸½¼ÂŪ¤Ë¤·ì´´ºÙ˦°Ü¿¢¤Ê¤É¤Î¼£ÎŤ¬¤Ç¤¤Ê¤¤¤¿¤áÁá´ü¤Ë»àË´¤¹¤ë½ÅÆƤʼÀ´µ | * | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA |
Âå¼Õ | ¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼·ç»¾É | Pyruvate kinase Deficiency | ÉϷ졢Ƭ³¸°Û¾ï¡£ATP»ºÀ¸Äã²¼¢ªK¤È¿å¤ÎºÙ˦³°¤Ø¤Îή½Ð¢ªÀÖ·ìµåÆâæ¿å¢ªÍÛùÀÖ·ìµå¢ªç£Â¡¤Ç½èÍý¡Ê·ì´É³°ÍÏ·ì¡Ë¢ªç£¼ð | AR | ¥Ð¥¤¥ª¥¹ |
»à»º¡¢¿·À¸»ù»àË´ ¡¦»é¼Á¤È·ìÀò¤Î°å³Ø¡Ö½½Ê¬¤Ë¿©±Â¤òÀݼ褷¤Æ¤¤¤ë»þ¤ÎÂå¼Õ¡×http://hobab.fc2web.com/sub4-shokuji.htm ¡¦°å³Ø¥Î¡¼¥ÈVer.2¡Ö¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼·ç»¾É¡×¥ê¥ó¥¯ |
IDIDA | ||||||
»°É© | ||||||
Pyruvate Kinase Deficiency(PK) | GTG |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ,¶,· | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
Von Willebrand's Disease(vWD)Typeµ | »°É© |
¶Ú¹ü³Ê·Ï | ¹ü·ÁÀ®ÉÔÁ´¾É | Osteogenesis Imperfecta | °×¹üÀÞÀ¡¦¿Ê¹ÔÀ¤Î¹üÊÑ·Á¤Ê¤É¤Î¹üÀȼåÀ¤ò¼¨¤¹É¾õ¤Ë²Ã¤¨¡¢ÍÍ¡¹¤ÊÄøÅ٤ηë¹çÁÈ¿¥¤Îɾõ¤ò¼¨¤¹ÀèÅ·À¤Î¼À´µ¡£À®Ä¹¤¬ÃÙ¤¤¡¢¾®¤Ö¤ê¡¢ÇòÌܤ¬ÀĤ¤¡¢ÉÔÀµÒû¹ç¡¦·ç»õ¡¢ÆñÄ°¡¢´ØÀᡦÈéÉæ¤Î²á¿¤Ê¤É¡£ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
IDIDA | ||||||
Âå¼Õ | ¥Ô¥ë¥Ó¥ó»À¥¥Ê¡¼¥¼·ç»¾É | Pyruvate Kinase Deficiency(PK) | ¡£ | * | GTG | ¡£ |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | * | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ÀèÅ·ÀÄäºßÀÌëÌÕ¾É | Congenital Stationary Night Blindness(CSNB) | Û¸ÂΤη绡¦°Û¾ï¡£ÌëÌդδü´Ö¤¬Á᤯¤«¤é»Ï¤Þ¤ê¡¢À®¸¤°Ê¹ß¤Ë¼ºÌÀ¤Ë¤¤¤¿¤ë¤³¤È¤â¤¢¤ë¤¬¿íÂΤ˰ÛÊѤ¬µ¯¤¤Ê¤±¤ì¤ÐÌëÌܤ¬¤¤«¤Ê¤¤¤À¤±¤È¤Ê¤ë¡£ cone-¥³¡¼¥ó-¿íÂÎ(¤¹¤¤¤¿¤¤)¤ÏÌÀ¤ë¤¤½ê¤Ç¿§¤ò¸«Ê¬¤±¤ë±ß¿í¾õ¤Î»ëºÙ˦¡£°Å¤¤¾ì½ê¤Ç¤Ï¿§¤ò¼±Ê̤Ǥ¤Ê¤¤¡£rod-¥í¥Ã¥É-Û¸ÂÎ(¤«¤ó¤¿¤¤¡Ë¤Ï°Å¤¤¾ì½ê¤ÇÌÀ°Å¤ò´¶¤¸¤ëËÀ¾õ¤Î»ëºÙ˦¡£¥Ò¥È¤Î¾ì¹çÌÀ¤ë¤¤¾ì½ê¤«¤é°Å¤¤¤È¤³¤í¤ËÆþ¤Ã¤¿»þ¤Ë¤â¤Î¤¬¸«¤¨¤ë¤è¤¦¤Ë¤Ê¤ë¤Þ¤Ç»þ´Ö¤¬¤«¤«¤ë¤¬¡¢¤³¤Î»þ¤Ë¥³¡¼¥ó¤È¥í¥Ã¥É¤ÎÀÚ¤êÂؤ¨¤¬µ¯¤¤Æ¤¤¤ë¡£ | AR(AD¤â) | GTG |
·ì±Õ | B·¿·ìͧÉ | * | * | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ¾ïÀ÷¿§ÂÎÍ¥À°äÅÁ¿Ê¹ÔÀÌÖËì°à½Ì¾É | Dominant PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AD | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£
|
ÌÜ | °äÅÁÀÇòÆâ¾ã | Cataracts | ¿å¾½ÂΤÎÇòÂù¡£Ï·ÎðÀ¡¢ÅüÇ¢ÉÂÀ¡¢³°½ýÀ¡¢ÆâʬÈçÀ¡¢ÃæÆÇÀ¤Î¸åÅ·À¤Î¤â¤Î¤È¼ãǯÀ(Ìܰ¤Ȥ·¤Æ6ºÐ°ÊÁ°)¡£¼ºÌÀ¡£PRA¤Î¹çÊ»¾É¤È¤·¤Æ¤â¸½¤ì¤ë¡£¿Ê¹ÔÅٹ礤¤¬µÞ¤Ç¤¢¤ì¤ÐÅüǢɤ⵿¤¨¤ë¡£Áá´üȯ¸«¤Ç¤¤¿¤éÆâÉþÌô¤ÈÅÀ´ãÌô¤Ç¿Ê¹Ô¤òÃ٤餻¤ë¼£ÎŤ¬¤Ç¤¤ë¾ì¹ç¤â¿¤¤ | AD | »°É© |
Âå¼Õ | ƼÃßÀѾɡ¢¥¦¥£¥ë¥½¥óÉ | Copper toxicosis | Äã¿©Íß¡¢Âç¿Í¤·¤¤¡¢»¶Ê⤬¶ì¼ê(Êâ¹Ô¾ã³²)¡¢È¯Ç®¡¢²«áÕ¡¢´Îµ¡Ç½¾ã³²(GOT¡¦GPT¡¦¥Ó¥ê¥ë¥Ó¥ó¤Ê¤É¤Î¾å¾º)¡¢´Î¼ðÂ硢磼ðÂ硢ʢ¿å¡¢Éâ¼ð¡¢Ìܤ理ÎÊѲ½¡¢ÍÏ·ìÀÉÏ·ì¡¢·ìÇ¢¡¢´ØÀá¾ã³² ´Î·¿¡¢¿À·Ð·¿¡¢´Î¡¦¿À·Ð·¿¤Î»°·¿¤Ëʬ¤±¤é¤ì¤ë¡£Ä㥻¥ë¥í¥×¥é¥¹¥ß¥ó·ì¾É¤òʻȯ¤¹¤ë¡£ ¥Ò¥È¤Î¾ì¹ç¤Ï´Î¾ã³²¤Î½ê¸«¤È¥»¥ë¥í¥×¥é¥¹¥ß¥óÄãÃͤȥ«¥¤¥¶¡¼¡¦¥Õ¥é¥¤¥·¥ã¡¼³ÑËìÎؤò³Îǧ¤Î¤¦¤¨´ÎÀ¸¸¡¤Ç³ÎÄꤵ¤ì¤ë¤è¤¦¤À¡£ |
AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
Copper Toxicosis(CT) | GTG | |||||
»°É© |
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Type¶ | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ¥³¥ê¡¼¥¢¥¤¡¢¥³¥ê¡¼´ã°Û¾ï | CEA, Collie eye anomaly | »ëÎϤ¬½ù¡¹¤ËÍî¤Á¤ë¤¬¸¤¤Ï¤½¤ÎÅÔÅÙ¼þ°Ï¤ËÂбþ¤·¤Æ¤¤¤¯¤Î¤Çµ¤ÉÕ¤¤Ë¤¯¤¤¡£½ÅÅ٤ξì¹ç¤ÏÌÖËì¤Ï¤¯Î¥¤òµ¯¤³¤·¼ºÌÀ¤Ë»ê¤ë¡£°äÅÁ»Ò¿ÇÃǰʳ°¤Ç¤ÏÀ®¸ì¤«·îÁ°¸å¤ËÀìÌç¤Î¸¡ºº¤ò¤·¤Æ¿ÇÃǤǤ¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
Collie Eye Anomaly(CEA/CH) | GTG | |||||
Âå¼Õ | ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É¡¢CLÉ | CL disease, Ceroid lipofuscinosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¿À·ÐºÙ˦¤ËÏ·ÇÑʪ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥Á¥ó¤òÃßÀѤµ¤»¤ë¿·ÄÄÂå¼Õ¤Î¾ã³²¡£3ºÐÁ°¤Ë»àË´ | AR | ¥Ð¥¤¥ª¥¹ | CLN5°äÅÁ»Ò |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
Neuronal Ceroid Lipofuscinosis(CL) | GTG | ¸¦µæ¤Î¤¿¤á¤Î´óÉÕAUS$10´Þ¤ß$52.50¡Á | ||||
JBCHN | ¸¦µæ¤Î¤¿¤á¤Î´óÉÕAUS$10´Þ¤ß\6,000 | |||||
¥À¡¼¥¦¥£¥ó | CLN5°äÅÁ»Ò | |||||
·ì±Õ | ¼þ´üÀ¹¥Ãæµå¸º¾¯¾É/¥°¥ì¡¼¥³¥ê¡¼¾É¸õ·² | Cyclic neutropenia/Gray collie syndrome | 10Æü¡Á¼þ´üŪ¤Ë·«¤êÊÖ¤¹È¯Ç®¡¢¸ý¹ÐÆâÄÙáç¡¢ÈéÉæ´¶À÷¾É | AR | ¥Ð¥¤¥ª¥¹ | ¹¥Ãæµå¤ÏÇò·ìµå¤Î¹½À®À®Ê¬¤Ç¡¢¼ç¤ËºÙ¶Ý¤ä¿¿¶Ý¤ËÂФ·¤Æ´¶À÷¤òËɤ° |
ÌÓ¿§ | ¥À¥Ã¥×¥ë¡¢¥Þ¡¼¥ë | Dapple/Merle | Í¥À¤ÎÌÓ¿§°äÅÁ»Ò¤ÇÍ¥ÀM¤ÏȾÃ×»à°äÅÁ»Ò¡¢MM¥Û¥âÀܹç¤Ç¤Ï¹â¤¤³ÎΨ¤ÇÃ×̿Ū¤È¤Ê¤ë¡£ÌӤ理äÊÁ¤À¤±¤Ç¤Ê¤¯ÂÛÆâ¤Çȯ㤹¤ëºÝ¿À·ÐÄéºÙ˦¤Ë°Û¾ï¤ÊƯ¤¤«¤±¤ò¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¥«¥é¡¼¤Ø¤Î±Æ¶Á¤À¤±¤Ç¤Ê¤¯¡¢µõ¼å¡¢Ä°³Ð¾ã³²¡¦¾®´ã¾É¡¦´ã°µ¾å¾º¡¦¼å»ë¡¢¿À·Ð°Û¾ï¤òµ¯¤³¤¹¡£ ¥·¥ó¥°¥ë¥Þ¡¼¥ë¤Î37%¤ËÆñÄ°¡¦¿§³Ð°Û¾ï(·ÚÅÙ¡Á½ÅÅÙ¤Þ¤ÇÍÍ¡¹¤À¤È»×¤ï¤ì¤ë)¤ò¼¨¤¹¤È¤Î¸¦µæ·ë²Ì¤â¤¢¤ë |
AD | ¥Ð¥¤¥ª¥¹ | ¥Þ¡¼¥ë¤Îȯ¸½ÌÌÀѤϥé¥ó¥À¥à¤Ê¤¿¤á¡¢¸ÄÂΤˤè¤Ã¤Æ¤Ï¸«Íî¤È¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ç¤³¤Î¸¡ºº¤Ï¥Þ¡¼¥ë¤«¤é»º¤Þ¤ì¤¿¥Ð¥¤¥«¥é¡¼(¤È¤¯¤Ë¥ì¥Ã¥É)¤âÈË¿£ÍÑÅӤǤ¢¤ì¤Ð¤ª¤³¤Ê¤Ã¤Æ¤ß¤ë²ÁÃͤϤ¢¤ë |
ÌÜ | prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | * | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£
|
ÌÜ | °äÅÁÀÇòÆâ¾ã | Cataracts | ¿å¾½ÂΤÎÇòÂù¡£Ï·ÎðÀ¡¢ÅüÇ¢ÉÂÀ¡¢³°½ýÀ¡¢ÆâʬÈçÀ¡¢ÃæÆÇÀ¤Î¸åÅ·À¤Î¤â¤Î¤È¼ãǯÀ(Ìܰ¤Ȥ·¤Æ6ºÐ°ÊÁ°)¡£¼ºÌÀ¡£PRA¤Î¹çÊ»¾É¤È¤·¤Æ¤â¸½¤ì¤ë¡£¿Ê¹ÔÅٹ礤¤¬µÞ¤Ç¤¢¤ì¤ÐÅüǢɤ⵿¤¨¤ë¡£Áá´üȯ¸«¤Ç¤¤¿¤éÆâÉþÌô¤ÈÅÀ´ãÌô¤Ç¿Ê¹Ô¤òÃ٤餻¤ë¼£ÎŤ¬¤Ç¤¤ë¾ì¹ç¤â¿¤¤¡£ | AD | IDIDA | |
»°É© | ||||||
GTG |
ÌÜ | ¾ïÀ÷¿§ÂÎÍ¥À°äÅÁ¿Ê¹ÔÀÌÖËì°à½Ì¾É | Dominant PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AD | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£
|
Âå¼Õ | ¥°¥ê¥³¡¼¥²¥óÃù¢É ¡¢Åü¸¶É | Glycogen storage disease | Î¥Æý´üº¢¤«¤éÓÒÅÇ¡¦¥¿¡¼¥ëÍͤβ¼Î¡¡¦¤è¤À¤ì¡¦¶ÚÆù¤¬¼å¤¤¤¿¤áÊâ¹Ôº¤Æñ¡¦¤±¤¤¤ì¤óȯºî¡¦¼º¿À¡¦Âβ¹Äã²¼¤Ê¤É¤ò¼¨¤·½Å¾É¤Î¾ì¹ç¤Ïºª¿ç¡¦¿ê¼å¤·»àË´¤Ë»ê¤ë¡£¾®¤Ö¤ê¡£¿·À¸»ù´ü¤òĶ¤¨¤ë¤ÈÄã·ìÅü¾É¡£·ÚÅ٤ʤâ¤Î¤ÏÄã·ìÅü¾É¤À¤±¤¬ÌÜΩ¤Ä¾ì¹ç¤â¤¢¤ë¡£µðÂç¿©Æ»¾É¡¢¤Æ¤ó¤«¤ó¤ò¹çÊ»¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´
´Î¡¤Î¼ç¤ÊƯ¤¤Ï¿©¤Ù¤¿¤â¤Î¤«¤é¥¨¥Í¥ë¥®¡¼¤òºî¤êÃù¢¤¹¤ë¤³¤È¡£Ä²´É¤«¤éµÛ¼ý¤µ¤ì¤¿Ã±ÅüÎà¤Ç¤¢¤ë¥°¥ë¥³¡¼¥¹¡á¥Ö¥É¥¦Åü(À¸ÂΤˤȤäƼçÍפʥ¨¥Í¥ë¥®¡¼¸»)¤ÏÌçÌ®¤òή¤ì¤Æ´Î¡¤Ë±¿¤Ð¤ì¤ë¡£¥°¥ë¥³¡¼¥¹¤ÏÃù¢¤Ë¤Ï¸þ¤¤¤Æ¤¤¤Ê¤¤À¼Á¤ò»ý¤Ã¤Æ¤¤¤ë¤¿¤á´Î¡¤Ï¥°¥ë¥³¡¼¥¹¤«¤é¥°¥ê¥³¡¼¥²¥ó¤È¤¤¤¦Â¿ÅüÎà¤ò¹çÀ®¤·Ãù¢¤¹¤ë¡£Åü¸¶É¤ϥ°¥ê¥³¡¼¥²¥ó¤òʬ²ò¡¦¹çÀ®¤¹¤ë¹ÚÁǤ¬·ç»¤¹¤ë¤¿¤á°Û¾ï¤ËÃßÀѤµ¤ì¤ë¡£ Ä̾ï¤Ï¶õÊ¢¤Ë¤Ê¤ë¤È´Î¡¤ËÃߤ¨¤é¤ì¤Æ¤¤¤ë¥°¥ê¥³¡¼¥²¥ó¤«¤é¥Ö¥É¥¦Åü¤¬ºî¤é¤ì·ìÃæ¤ËÊü½Ð¤µ¤ì¤ë¤¬¡¢¥°¥ê¥³¡¼¥²¥ó¤¬Î±¤Þ¤Ã¤¿¤Þ¤Þ¤À¤È´Î¡¤Î¼ð¤ì¤äÄã·ìÅü¤¬µ¯¤³¤ë¡£¿ÇÃǤ϶ÚÀ¸¸¡¡£ |
IDIDA | ||||||
Ia·¿Åü¸¶É | * | ¡Ö¥°¥ë¥³¡¼¥¹¹ÚÁǤη绤ˤè¤ê¹âÆý»À·ì¾É¡¢¹âÇ¢»À·ì¾É¡¢È¯°é¾ã³²¡¢Äã·ìÅüȯºî¡¢ÓÒÅÇ¡¢¿Ê¹ÔÀÁ´¿ÈÀ¶Úµõ¼å¡¢´Î¼ðÂç¡¢µðÂç¿©Æ»¾É¡¢¹â»é·ì¾É¡×(¥ê¥Æ¥¤¥ë) | * | ¥ê¥Æ¥¤¥ë | ||
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | Von Willebrand's Disease(vWD)Typeµ,¶,· | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤È¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | GTG | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | Type A ¿Ê¹ÔÀÌÖËì°à½Ì¾É | Type A PRA | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | * | GTG | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¶Ú·ë¹çÁÈ¿¥ | ÀèÅ·À¶Ú¶ÛÄ¥¾É | Myotonia congenita | ¡Ö¥¯¥í¥é¥¤¥É¥¤¥ª¥ó¥Á¥ã¥ó¥Í¥ë¤Î°Û¾ï¤Ë¤è¤Ã¤Æ¡¢¶ÚÆù¤ÎÃд˺îÍѤËɬÍפʥ¯¥í¥é¥¤¥É¥¤¥ª¥ó¤ÎºÙ˦ÆâήÆþ¤¬¸º¾¯¤¹¤ë¤¿¤á¤Ëµ¯¤³¤ë¼À´µ¤Ç¤¹¡£¡×(¥ê¥Æ¥¤¥ë) | * | ¥Ð¥¤¥ª¥¹ | |
¥ê¥Æ¥¤¥ë | ||||||
IDIDA |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¥«¥Û¥Æ¥¯¥Î | ¥í¥ó¥°¥Ø¥¢¡¼¥É¤Î¤ß | |||||
IDIDA | ¥í¥ó¥°¥Ø¥¢¡¼¥É¤Î¤ß | |||||
Cord1-PRA | »°É© | ¥í¥ó¥°¡¢¥¹¥à¡¼¥¹¡¢¥ï¥¤¥¢¡¼¶¦ | ||||
Âå¼Õ | ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥¹¥Á¥ó¾É¡¢CLÉ | CL disease, Ceroid lipofuscinosis | ¥é¥¤¥½¥¾¡¼¥à¼À´µ¿À·ÐºÙ˦¤ËÏ·ÇÑʪ¥»¥í¥¤¥É¥ê¥Ý¥Õ¥Á¥ó¤òÃßÀѤµ¤»¤ë¿·ÄÄÂå¼Õ¤Î¾ã³²¡£3ºÐÁ°¤Ë»àË´ | AR | ¥Ð¥¤¥ª¥¹ | IDIDA |
ÌÓ¿§ | ¥À¥Ã¥×¥ë¡¢¥Þ¡¼¥ë | Dapple/Merle | Í¥À¤ÎÌÓ¿§°äÅÁ»Ò¤ÇÍ¥ÀM¤ÏȾÃ×»à°äÅÁ»Ò¡¢MM¥Û¥âÀܹç¤Ç¤Ï¹â¤¤³ÎΨ¤ÇÃ×̿Ū¤È¤Ê¤ë¡£ÌӤ理äÊÁ¤À¤±¤Ç¤Ê¤¯ÂÛÆâ¤Çȯ㤹¤ëºÝ¿À·ÐÄéºÙ˦¤Ë°Û¾ï¤ÊƯ¤¤«¤±¤ò¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¥«¥é¡¼¤Ø¤Î±Æ¶Á¤À¤±¤Ç¤Ê¤¯¡¢µõ¼å¡¢Ä°³Ð¾ã³²¡¦¾®´ã¾É¡¦´ã°µ¾å¾º¡¦¼å»ë¡¢¿À·Ð°Û¾ï¤òµ¯¤³¤¹¡£ ¥·¥ó¥°¥ë¥Þ¡¼¥ë¤Î37%¤ËÆñÄ°¡¦¿§³Ð°Û¾ï(·ÚÅÙ¡Á½ÅÅÙ¤Þ¤ÇÍÍ¡¹¤À¤È»×¤ï¤ì¤ë)¤ò¼¨¤¹¤È¤Î¸¦µæ·ë²Ì¤â¤¢¤ë |
AD | ¥Ð¥¤¥ª¥¹ | ¥À¥Ã¥×¥ë(¥Þ¡¼¥ë)¤Îȯ¸½ÌÌÀѤϥé¥ó¥À¥à¤Ê¤¿¤á¡¢¸ÄÂΤˤè¤Ã¤Æ¤Ï¸«Íî¤È¤¹¤³¤È¤¬¤¢¤ë¤Î¤Ç¤³¤Î¸¡ºº¤Ï¥ì¥Ã¥É¥À¥Ã¥×¥ë¡¦¥¯¥ê¡¼¥à¥À¥Ã¥×¥ë¤Ê¤É¥Ù¡¼¥¹¤ÎÌÓ¿§¤¬°ì¿§¤Î¸ÄÂΤ䡢¼ª¤À¤±Çò¤¤ÌÓ¤¬À¸¤¨¤Æ¤¤¤ë¥Ö¥é¥Ã¥¯¥¿¥ó¤Ê¤É¤Ë¡¢¤è¤ê͸ú¤È»×¤ï¤ì¤ë |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | GTG | ||||
·ì±Õ | ¥Õ¥©¥ó¥¦¥£¥ë¥Ö¥é¥ó¥ÉÉ | von Willebrand's disease | µ¶·ìͧÉ¡£¡Ö·ì±Õ¤Î¶Å¸Ç¤Ë´Ø¤ï¤ë¥Õ¥©¥ó¡¦¥¦¥£¥ë¥Ö¥é¥ó¥È¡«°ø»Ò¡ÊvWF¡Ë¤¬ÉÔ¤·¤¿¤ê¡¢µ¡Ç½°Û¾ï¤Ë¤è¤êµ¯¤³¤ë¡£ÆÃħ¤Ï½Ð·ì¤·¤ä¤¹¤¯¡¢»ß·ì¤·¤Ë¤¯¤¤·¹¸þ¤Ë¤Ê¤ë¤³¤È¤Ç¤¢¤ê¡¢Ì¿¤Ë´Ø¤ï¤ë¤³¤È¤â¤¢¤ê¤¨¤Þ¤¹¡£¶ñÂÎŪ¤Ê¾É¾õ¤è¤·¤Æ¡¢»õ·Ô¤äÉ¡¤ÎÇ´Ëì¤Î½Ð·ì¡¢Èé²¼¤Î½Ð·ì¡¢·ìÇ¢¡¢·ìÊØ¡×(¥ê¥ó¥¯¥¹) | AR | ¥Ð¥¤¥ª¥¹ | »à»º¡¢¿·À¸»ù»àË´ |
¥«¥Û¥Æ¥¯¥Î | ||||||
IDIDA |
·ì±Õ | B·¿·ìͧÉ | * | * | AR | »°É© | »à»º¡¢¿·À¸»ù»àË´ |
ÌÜ | ¿Ê¹ÔÀÌÖËì°Ñ½Ì¾É | Progressive retinal atrophy | ¿Ê¹ÔÀÌÖËìÊÑÀ¤È¤Ê¤ëɵ¤¤ÎÁí¾Î¡£°ìÈÌŪ¤ËÀ¸¸å5¥ö·îº¢¤«¤éǧ¤á¤é¤ì¡¢ÌëÌÕ¡¦¤Ä¤Þ¤Å¤¡¦¤Ö¤Ä¤«¤ê¡¦³¬ÃʤäÃʺ¹¤Ç¤¹¤¯¤à¡¢¤Ê¤É¤ò·Ð¤Æ»ëÎϤ¬Äã²¼¤·¼ºÌÀ¤¹¤ë¡£Äˤߤòȼ¤¦¤³¤È¤â¤¢¤ë¤è¤¦¤À¡£ÇòÆâ¾ã¤äÎÐÆâ¾ã¤Ê¤É¤Û¤«¤ÎÌܤÎɵ¤¤òʻȯ¤¹¤ë¤³¤È¤â¤¢¤ë¡£ | AR | ¥Ð¥¤¥ª¥¹ | ¥¿¥¤¥×¤ä¸ÄÂΤˤè¤Ã¤Æȯ¾ÉǯÎð¤Ï¿ô¥ö·î¡Á12ºÐ¡£¸¤¤Ç¤ÏÌÖËìÁ´ÂΤˤ錄¤ë¤Ó¤Þ¤óÀ¿Ê¹ÔÀÌÖËì°à½Ì¤¬Â¿¤¤¡£ |
IDIDA | ||||||
prcd¿Ê¹ÔÀÌÖËì°à½Ì¾É | prcd-PRA | GTG | ||||
Ǿ¿À·Ð | ȯºîÀ¿ç̲¡¢¥Ê¥ë¥³¥ì¥×¥·¡¼ | Narcolepsy | ´¶¾ð¤¬¹â¤Þ¤Ã¤¿ºÝ(¤ª¤ä¤Ä¤ò¿©¤Ù¤ë»þ¡¢»¶Êâ¤Ë½Ðȯ¤¹¤ë»þ¤Ê¤É)¤Ë¿ôÉáÁ¿ô½½ÉäÎæÎÏȯºî¤¬µ¯¤³¤ë¡£È¯ºî¤ÏÄ̾ïÀ¸Ì¿¤Î´íµ¡¤Ï̵¤¤¡£ | AR | ¥Ð¥¤¥ª¥¹ | |
IDIDA | ||||||
GTG | ||||||
¿ÕǢϩ¼À´µ | ¥·¥¹¥Á¥óÇ¢¾É | Cystinuria(CYN) | ºÆµÛ¼ý¤µ¤ì¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¥·¥¹¥Á¥ó¤È¤¤¤¦¤¿¤ó¤Ñ¤¯¼Á¤¬Ç¢¤Ë½Ð¤Æ¤·¤Þ¤¦¤³¤È¤Ë¤è¤Ã¤Æ·ëÀФ¬ºî¤é¤ì¤ë¡£Ç¢¤Îph¤Ï°Û¤Ê¤ë¤¬¡¢¥¹¥È¥ë¥Ð¥¤¥È·ëÀФòʻȯ¤¹¤ë¤³¤È¤â¤¢¤ê¡¢¥¹¥È¥ë¥Ð¥¤¥È¤Î¼£ÎŤ¬¤¦¤Þ¤¯¿Ê¤Þ¤Ê¤¤»þ¤Ïµ¿¤¨¤ë¡£¥Û¥âÀܹç¤Î¾ì¹ç¤Ï·ëÀФȤʤ뤬¡¢¥Ø¥Æ¥í¤Ç¤Ï·ëÀФϷÁÀ®¤µ¤ì¤Ê¤¤¤¬Ä̾ï¤è¤ê¿¤¤¥·¥¹¥Á¥ó¤¬ÇӽФµ¤ì¤Æ¤¤¤ë¡£ | AR | GTG | |
¶Ú·ë¹çÁÈ¿¥ | Ãæ¿´³Ë¥ß¥ª¥Ñ¥·¡¼ ¶Ú¥¸¥¹¥È¥í¥Õ¥£¡¼ |
* | * | AR | »°É© |